Following recent positive top-line Phase II results for their BACE inhibitor elenbecestat, Eisai Co. Ltd. and partner Biogen Inc. have notched up further progress in Alzheimer's for another of their approaches to the disease, the amyloid-targeting antibody BAN2401.
In a final analysis of the 856-patient Phase II study at 18 months, the therapy - which targets amyloid beta protofibrils by selectively binding to and neutralizing soluble, toxic amyloid beta aggregates - showed a statistically significant